denovoSkin -Unique Personalized Skin Technology
To bio-engineer denovoSkin™, a small biopsy of healthy skin is harvested from the patient. The biopsy is processed to isolate epidermal and dermal cells. The cells are expanded in vitro, and thereafter used in combination with a hydrogel to create a dermo-epidermal skin graft. denovoSkin™ is now ready to be transplanted on the patient’s wounds. The safety trials for denovoSkin™ have been completed. The efficacy trials are currently being conducted at various hospitals in Switzerland and the EU and are supported by Wyss Zurich.
denovoSkin™ has a large potential. It could be of great benefit for patients with burns, traumas, that undergo reconstructive or plastic procedures, as well as for patients with chronic ulcers or congenital malformations that lead to skin-related problems.
denovoSkin™ is a patented, personalized, autologous bio-engineered human skin graft classified as Advanced Therapy Medicinal Product (ATMP). It is engineered in large quantities starting-off from a stamp-sized skin biopsy of the patient, thus solving the donor site shortage issue. Moreover, because of its dermo-epidermal structure, denovoSkin™ leads to minimal scarring after transplantation.
Its outstanding performance could considerably reduce or even avoids further corrective interventions, allowing for considerable savings. denovoSkin™ is also granted with Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA.